Author

Cristina Barrenetxea Lekue

Observed names: C. Barrenetxea Lekue, Cristina de Barrenetxea Lekue, Lekue, Cristina Barrenetxea

Institution: Hospital de Basurto

Observed institution: Hospital de Basurto

ORCID: 0000-0002-9777-8788

Observed ORCID: 0000-0002-9777-8788

OpenAlex ID: A5074872799

Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria

2024 · Phillip Scheinberg, Diego Villa Clé, et al. · American Journal of Hematology · 52

Pixantrone beyond monotherapy: a review

2019 · Cristina Barrenetxea Lekue, Silvina Grasso Cicala, et al. · Annals of Hematology · 23

Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non‐Hodgkin B‐cell lymphomas

2020 · Juan‐Manuel Sancho, Belén Navarro, et al. · European Journal Of Haematology · 10

S183: Phase Iii Randomized, Multicenter, Open-label Commodore 1 Trial: Comparison of Crovalimab Vs Eculizumab in Complement Inhibitor-experienced Patients With Paroxysmal Nocturnal Hemoglobinuria (pnh)

2023 · Phillip Scheinberg, Diego Cle, et al. · HemaSphere · 5

Nivolumab for Heavily Pretreated Relapsed/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO)

2018 · Carmen Martinez, Cecilia Carpio, et al. · Blood · 2

Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma

2025 · Mariana Bastos-Oreiro, Gloria Iacoboni, et al. · Blood

Prognostic variables associated with the development of cytokine release syndrome after bispecific antibodies in non-Hodgkin lymphoma patients – the geltamo (Spanish Lymphoma Group) experience

2025 · Angel Serna, Gloria Iacoboni, et al. · Blood

Study design of A phase 3, open-label trial for pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria with inadequate control of intravascular hemolysis

2025 · Jun Ho Jang, Cristina Barrenetxea Lekue, et al. · Blood

Geriatric assessment in hematology (GAH) scale for survival prognostication and early treatment discontinuation in older adults: Final results from the spanish hematogeriatric registry

2025 · Isabel González-gascón-y-Marín, Dolly Viviana Fiallo Suarez, et al. · Blood

COMMODORE 1: Crovalimab demonstrates 2-year efficacy and safety in switch patients with paroxysmal nocturnal haemoglobinuria

2025 · Yenerel, Mustafa N., Cle, Diego Villa, et al. · RWTH Publications (RWTH Aachen)

Essai de phase III randomisé, multicentrique et en ouvert COMMODORE 1 : comparaison du crovalimab et de l’éculizumab chez des patients atteints d’hémoglobinurie paroxystique nocturne (HPN) déjà traités par un inhibiteur du complément

2024 · C. Tessier, L. Terriou, et al. · La Revue de Médecine Interne

Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab

2024 · Phillip Scheinberg, Diego Villa Cle, et al. · Blood

Works count: 12

Citation count: 92

H-index: 4

I10-index: 3